Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer
D Merino, SW Lok, JE Visvader, GJ Lindeman
Oncogene | NATURE PUBLISHING GROUP | Published : 2016
Awarded by NHMRC
Awarded by National Breast Cancer Foundation
Awarded by Victorian Cancer Agency
We thank P Maltezos for assistance with the figures, G Lessene for advice and F Vaillant for helpful comments on the manuscript. We apologize to authors whose contributions have not been cited due to space limitations. Our research in this area is supported by grants from the NHMRC (1016701, 1040978), National Breast Cancer Foundation (NC-13-21, NT-13-06), the Victorian Cancer Agency (TRP13041) and the Victorian Government. DM is supported by an Early Career Fellowship from the National Breast Cancer Foundation (ECF-13-06), JEV by an Australia Fellowship and GJL by a Research Fellowship from the NHMRC (1078730).